OncoMatch/Clinical Trials/NCT06498752
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Is NCT06498752 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PD-1 monoclonal antibody consolidation therapy for esophageal cancer.
Treatment: PD-1 monoclonal antibody consolidation therapy — To further validate the performance of the high-sensitivity MRD assay in patients with squamous esophageal cancer who have completed radical radiotherapy; to validate whether MRD-negative patients can maintain a good prognosis under regular follow-up; and to validate whether MRD-positive patients can improve their survival with consolidation therapy with PD-1 monotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radiation therapy — definitive/radical
Completed radical radiotherapy (dose 50-60Gy)
Must have received: platinum-based chemotherapy — systemic
Received a systemic regimen of platinum in combination with paclitaxel
Must have received: taxane (paclitaxel) — systemic
platinum in combination with paclitaxel
Must have received: antimetabolite (5-FU) — systemic
5-FU-based two-drug regimen
Must have received: antimetabolite (S-1) — systemic
S-1 monotherapy in elderly patients
Cannot have received: systemic therapy (chemotherapy alone or chemotherapy combined with immunotherapy)
Received systemic therapy (chemotherapy alone or chemotherapy combined with immunotherapy) for more than 4 cycles
Lab requirements
Blood counts
no significant abnormality
Kidney function
no significant abnormality
Liver function
no significant abnormality
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06498752 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy (chemotherapy alone or chemotherapy combined with immunotherapy) disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III or IVA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages